scholarly journals RNA binding protein RBM3 increases β-catenin signaling to increase stem cell characteristics in colorectal cancer cells

2015 ◽  
Vol 55 (11) ◽  
pp. 1503-1516 ◽  
Author(s):  
Anand Venugopal ◽  
Dharmalingam Subramaniam ◽  
Julia Balmaceda ◽  
Badal Roy ◽  
Dan A. Dixon ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4092
Author(s):  
Marta Manco ◽  
Ugo Ala ◽  
Daniela Cantarella ◽  
Emanuela Tolosano ◽  
Enzo Medico ◽  
...  

RNA binding proteins are well recognized as critical regulators of tumorigenic processes through their capacity to modulate RNA biogenesis, including alternative splicing, RNA stability and mRNA translation. The RNA binding protein Epithelial Splicing Regulatory Protein 1 (ESRP1) can act as a tumor suppressor or promoter in a cell type- and disease context-dependent manner. We have previously shown that elevated expression of ESRP1 in colorectal cancer cells can drive tumor progression. To gain further insights into the pro-tumorigenic mechanism of action of ESRP1, we performed cDNA microarray analysis on two colorectal cells lines modulated for ESRP1 expression. Intriguingly, RAC1b was highly expressed, both at mRNA and protein levels, in ESRP1-overexpressing cells, while the opposite trend was observed in ESRP1-silenced CRC cells. Moreover, RAC1 and RAC1b mRNA co-immunoprecipitate with ESRP1 protein. Silencing of RAC1b expression significantly reduced the number of soft agar colonies formed by ESRP1-overexpressing cells, suggesting that ESRP1 acted, at least partially, through RAC1b in its tumor-promoting activities in CRC cells. Thus, our data provide molecular cues on targetable candidates in CRC cases with high ESRP1 expression.


2013 ◽  
Vol 144 (5) ◽  
pp. S-802
Author(s):  
Anand Venugopal ◽  
Deep Kwatra ◽  
Sivapriya Ponnurangam ◽  
Dharmalingam Subramaniam ◽  
Satish Ramalingam ◽  
...  

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Michalina Janiszewska ◽  
Mario-Luca Suva ◽  
Riekelt H. Houtkooper ◽  
Virginie Clement-Schatlo ◽  
Ivan Stamenkovic

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Anand Venugopal ◽  
Deep Kwatra ◽  
Shane Stecklein ◽  
Satish Ramalingam ◽  
Dharmalingam Subramaniam ◽  
...  

Gut ◽  
2020 ◽  
pp. gutjnl-2020-320652
Author(s):  
Lei Sun ◽  
Arabella Wan ◽  
Zhuolong Zhou ◽  
Dongshi Chen ◽  
Heng Liang ◽  
...  

ObjectiveDysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood.DesignWe analysed altered gene signatures during colorectal tumour progression, and used a complex of molecular and metabolic assays to study the regulation of metabolism in CRC cell lines, human patient-derived xenograft mouse models and tumour organoid models.ResultsWe identified a novel RNA-binding protein, RALY (also known as hnRNPCL2), that is highly associated with colorectal tumour aggressiveness. RALY acts as a key regulatory component in the Drosha complex, and promotes the post-transcriptional processing of a specific subset of miRNAs (miR-483, miR-676 and miR-877). These miRNAs systematically downregulate the expression of the metabolism-associated genes (ATP5I, ATP5G1, ATP5G3 and CYC1) and thereby reprogramme mitochondrial metabolism in the cancer cell. Analysis of The Cancer Genome Atlas (TCGA) reveals that increased levels of RALY are associated with poor prognosis in the patients with CRC expressing low levels of mitochondrion-associated genes. Mechanistically, induced processing of these miRNAs is facilitated by their N6-methyladenosine switch under reactive oxygen species (ROS) stress. Inhibition of the m6A methylation abolishes the RALY recognition of the terminal loop of the pri-miRNAs. Knockdown of RALY inhibits colorectal tumour growth and progression in vivo and in organoid models.ConclusionsCollectively, our results reveal a critical metabolism-centric role of RALY in tumour progression, which may lead to cancer therapeutics targeting RALY for treating CRC.


Sign in / Sign up

Export Citation Format

Share Document